What question did this study set out to answer?

This study aims to evaluate the prevalence of oral manifestations in individuals undergoing chemotherapy.

April 1, 2026

Prevalence of Oral Manifestations in Individuals Undergoing Chemotherapy: Systematic Review and Meta‐Analysis

VFValder Ferreira da Silva FilhoCentro Universitário de Sete Lagoas LMLetícia Rocha Dias da MottaCentro Universitário de Sete Lagoas LALucas Guimarães AbreuUniversidade Federal de Minas Gerais

Key Points

This study aims to evaluate the prevalence of oral manifestations in individuals undergoing chemotherapy.
Conducted a systematic review following PRISMA guidelines.
Included cross-sectional studies assessing oral manifestations related to chemotherapy.
Conducted searches in PubMed, Embase, Scopus, and Google Scholar for relevant literature.
Assessed risk of bias with JBI Critical Appraisal tools.
Synthesized results using MedCalc software.
Pooled prevalence of oral mucositis was 42.15%.
Xerostomia prevalence was reported at 39.92%.
Dysgeusia prevalence reached 49.62%.
The prevalence of oral candidiasis was 24.11%.
Gingivitis prevalence was identified at 56.15%.

Abstract

ABSTRACT Aim The aim of the present study was to investigate the prevalence of oral manifestations among patients undergoing chemotherapy. Methods A systematic review was conducted and followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses. The review was registered in PROSPERO, under registration number CRD42024564007. Two independent reviewers conducted searches in the PubMed, Embase, and Scopus databases as well as Google Scholar for grey literature in July 2024. Inclusion criteria comprised cross‐sectional studies that evaluated oral manifestations associated with chemotherapy. Risk of bias was assessed using JBI Critical Appraisal tool for cross‐sectional studies. Synthesis of the results was performed using the MedCalc software program. Results Twenty‐four cross‐sectional studies were included. After the analysis of the results, the pooled prevalence was estimated for the following oral manifestations: oral mucositis (42.15%); xerostomia (39.92%); dysgeusia (49.62%); candidiasis (24.11%); oral herpes (7.98%); oral ulcer (31.40%); gingivitis (56.15%); dysphagia (28.28%); halitosis (19.55%); oral pain (22.78%). Conclusion The evidence suggests that the prevalence oral manifestations is high in patients undergoing chemotherapy. However, the results should be interpreted with caution due to the considerable heterogeneity among the studies.

AI에게 질문

Bookmark

View Full Paper